| 发明名称 |
Solid forms of a macrocyclic kinase inhibitor |
| 摘要 |
This invention relates to crystalline solvates of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benz- oxadiazacyclotetradecine-3-carbonitrile, useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to pharmaceutical compositions comprising such crystalline solvates, and to methods of using such solvates and compositions in the treatment of abnormal cell growth in mammals, especially humans. |
| 申请公布号 |
US9637500(B2) |
申请公布日期 |
2017.05.02 |
| 申请号 |
US201414898582 |
申请日期 |
2014.06.17 |
| 申请人 |
Pfizer Inc. |
发明人 |
Jensen Andrew James;Luthra Suman;Richardson Paul Francis |
| 分类号 |
C07D213/65;A61K31/4439;C07D498/18 |
主分类号 |
C07D213/65 |
| 代理机构 |
|
代理人 |
Robinson Leslie A. |
| 主权项 |
1. A crystalline acetic acid solvate of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiaza-cyclotetradecine-3-carbonitrile, having a powder X-ray diffraction pattern comprising a peak at a 2θ value of: 12.9° 2θ±0.2° 2θ. |
| 地址 |
New York NY US |
